Indian Journal of Private Psychiatry

Register      Login

VOLUME 16 , ISSUE 2 ( July-December, 2022 ) > List of Articles

Original Article

Course of Sexual Dysfunction in Different Domains among Hypertensive Patients: A Longitudinal Study in a Tier 2 City in India

Ankit Halder, Navna Panchami Ravindran, Devavrat Harshe, Sneha Harshe, Gurudas Harshe, Avinanda Biswas, Dhakshana Pushpanathan, Abhishek Shewale, Sucharita Patra, Aditya Nair

Keywords : Course, Hypertension, Sexual dysfunction

Citation Information : Halder A, Ravindran NP, Harshe D, Harshe S, Harshe G, Biswas A, Pushpanathan D, Shewale A, Patra S, Nair A. Course of Sexual Dysfunction in Different Domains among Hypertensive Patients: A Longitudinal Study in a Tier 2 City in India. Ind J Priv Psychiatry 2022; 16 (2):78-84.

DOI: 10.5005/jp-journals-10067-0120

License: CC BY-NC 4.0

Published Online: 31-08-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Introduction: A greater risk of sexual dysfunction (SDys) is found in hypertensive individuals. The study aimed to chronicle the course of dysfunction in different domains of male and female sexual function in patients of essential hypertension and correlate the findings with different patient characteristics. Materials and methods: The study was conducted in a semi-urban outpatient department setting, in Kolhapur city, consisting of 360 patients of essential hypertension on antihypertensive therapy for at least 2 years fulfilling the criteria of the study protocol in General medicine OPD of DY Patil Hospital and Research Institute. Detailed clinical history, examination, and laboratory investigations were carried out. Clinical data were collected using standard questionnaires. Demographics and clinical data were analyzed in R-studio software (v.1.2.5001). Result: Of the 180 males, 46.11% (n = 83), and of 180 females, 38.89% (n = 70) had dysfunction in at least one domain. Among the 83 males with dysfunction, erectile dysfunction (Edys) was the commonest (100%) and lack of intercourse satisfaction (49%) was the least. Among the 70 females with dysfunction, lack of sexual desire was the commonest (78%) and lack of lubrication (46%) was the least. Age, antihypertensive drug type, and duration of antihypertensive treatment were significantly associated with dysfunction (p <0.005). Sexual dysfunction improved in all the 25 males and 23 females who took treatment for it in the form of drugs and psychotherapy. Conclusion: Sexual dysfunctions are more prevalent in hypertensive individuals. It should be aggressively screened, avoided, and treated since it is a sign of increased cardiovascular risk that also reduces the quality of life.

PDF Share
  1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2224–2260. DOI: 10.1016/S0140-6736(12)61766-8.
  2. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. The lancet. 2005;365(9455):217–223. DOI: 10.1016/S0140-6736(05)17741-1.
  3. Oaks WW and Moyer JH. Sex and hypertension. Med Aspects Hum Sex 1972.
  4. Doumas M, Tsiodras S, Tsakiris A, et al. Female sexual dysfunction in essential hypertension: a common problem being uncovered. J Hypertens 2006;24(12):2387–2392. DOI: 10.1097/01.hjh.0000251898.40002.5b.
  5. Ko DT, Hebert PR, Coffey CS, et al. β-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002;288(3):351–357. DOI: 10.1001/jama.288.3.351.
  6. Kaya C, Yilmaz G, Nurkalem Z, et al. Sexual function in women with coronary artery disease: a preliminary study. Int J Impot Res 2007;19(3):326–329. DOI: 10.1038/sj.ijir.3901530.
  7. Grimm Jr RH, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women: treatment of mild hypertension study (TOMHS). Hypertension 1997;29(1 Pt 1):8–14. DOI: 10.1161/01.hyp.29.1.8.
  8. Fagard R. Reappraisal of the European guidelines on hypertension management: the European Society of Hypertension Task Force document: a short review. Pol Arch Med Wewn 2010;120(1–2):31–35. PMID: 20150842.
  9. Garko SB, Ogunsina MO, Danbauchi SS. Sexual dysfunction in hypertensive patients: implications for therapy. Ann Afr Med 2005;4(2):46–51.
  10. Meston CM, Frohlich PF. The neurobiology of sexual function. Arch Gen Psychiatry 2000;57(11):1012–1030. DOI: 10.1001/archpsyc.57.11.1012.
  11. de Oliveira LFTS, Chiavegato LD, Arakaki JSO, et al. Prevalence of sexual dysfunction in women with pulmonary hypertension and associated factors. Heart & Lung 2021;50(5):714–719. DOI: 10.1016/j.hrtlng.2021.04.018.
  12. Viigimaa M, Doumas M, Vlachopoulos C, et al. Hypertension and sexual dysfunction: time to act. J Hypertens 2011;29(2):403–407. DOI: 10.1097/HJH.0b013e328342c659.
  13. Bansal SU. Sexual dysfunction in hypertensive men. A critical review of the literature. Hypertension 1988;12(1):1–0. DOI: 10.1161/01.HYP.12.1.1.
  14. Conaglen HM, Conaglen JV. Drug-induced sexual dysfunction in men and women. Aust Prescr 2013;36(2):42–45. DOI: 10.18773/austprescr.2013.021.
  15. Ker JA. Hypertension and sexual dysfunction. S Afr Fam Pract 2012;54(2):117–118. DOI: 10.1080/20786204.2012.10874189.
  16. Karadeniz T, Topsakal M, Aydogmus A, et al. Correlation of ultrastructural alterations in cavernous tissue with the clinical diagnosis vasculogenic impotence. Urol Int 1996;57(1):58–61. DOI: 10.1159/000282878.
  17. Weiss RJ. Effects of antihypertensive agents on sexual function. Am Fam Physician 1991;44(6):2075–2082. PMID: 1684081.
  18. Moss HB, Procci WR. Sexual dysfunction associated with oral antihypertensive medication: a critical survey of the literature. Gen Hosp Psychiatry 1982;4(2):121–129. DOI: 10.1016/0163-8343(82)90041-X.
  19. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34(28):2159–2219. DOI: 10.1093/eurheartj/eht151.
  20. Duncan LE, Lewis C, Jenkins Pet al. Does hypertension and its pharmacotherapy affect the quality of sexual function in women? Am J Hypertens 2000;13(6 Pt 1):640–647. DOI: 10.1016/s0895-7061(99)00288-5.
  21. Choy CL, Sidi H, Koon CS, et al. Systematic review and meta-analysis for sexual dysfunction in women with hypertension. J Sex Med 2019;16(7):1029–1048. DOI: 10.1016/j.jsxm.2019.04.007.
  22. Sadock VA. Normal human sexuality and sexual dysfunctions. In: Sadock BJ, Sadock VA, eds. Kaplan @ Sadock's Comprehensive Textbook of Psychiatry. 11th ed. Vol. 1. Philadelphia: Lippincott Williams and Wilkins; 2009:2027.
  23. World Health Organization. Gender and Reproductive Rights, Glossary, Sexual Health 2002. Available: from [Retrieved July 11,2003].
  24. Poulter NR, Castillo R, Charchar FJ, et al. Are the American Heart Association/American College of Cardiology high blood pressure guidelines fit for global purpose?: thoughts from the International Society of Hypertension. Hypertension 2018;72(2):260–262. DOI: 10.1161/HYPERTENSIONAHA.118.11452.
  25. Crooks J, Murray IP, Wayne EJ. Statistical methods applied to the clinical diagnosis of thyrotoxicosis. Q J Med 1959;28(110):211–234. PMID: 13658351.
  26. Billewicz WZ, Chapman RS, Crooks J, et al. Statistical methods applied to the diagnosis of hypothyroidism. Q J Med 1969;38(150):255–266. PMID: 4181088.
  27. Kumar N, Gupta N, Kishore J. Kuppuswamys socioeconomic scale: Updating income ranges for the year 2012. Indian J Public Health 2012;56(1):103. DOI: 10.4103/0019-557X.96988.
  28. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26(2):191–208. DOI: 10.1080/009262300278597.
  29. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49(6):822–830. DOI: 10.1016/s0090-4295(97)00238-0.
  30. Avasthi A, Grover S, Rao TS. Clinical practice guidelines for management of sexual dysfunction. Indian J Psychiatry 2017;59(Suppl 1):S91–S115. DOI: 10.4103/0019-5545.196977.
  31. Domanski MJ, Mitchell GF, Norman JE, et al. Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. J Am Coll Cardiol 1999;33(4):951–958. DOI: 10.1016/s0735-1097(98)00679-2.
  32. Burchardt M, Burchardt T, Baer L, et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000;164(4):1188–1191. PMID: 10992363.
  33. Llisterri JL, Vidal JVL, Vicente JA, et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001;321(5):336–341. DOI: 10.1097/00000441-200105000-00006.
  34. Nascimento ER, Maia ACO, Nardi AE, et al. Sexual dysfunction in arterial hypertension women: the role of depression and anxiety. Journal of affective disorders 2015;181:96–100. DOI: 10.1016/j.jad.2015.03.050.
  35. Goldstein I, Berman JR. Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insufficiency syndrome. Int J Impot Res 1998;10(Suppl 2):S84–S90. PMID: 9647967.
  36. Tarcan T, Park K, Goldstein I. Histomorphometric analysis of age-related structural changes in human clitoral cavernosal tissue. J Urol 1999;161(3):940–944. PMID: 10022730.
  37. Spatz ES, Canavan ME, Desai MM, et al. Sexual activity and function among middle-aged and older men and women with hypertension. J Hypertens 2013;31(6):1096–1105. DOI: 10.1097/HJH.0b013e32835fdefa.
  38. Kinsey AC, Pomeroy WB, Martin CE. Sexual behavior in the human male. Philadelphia and London. B: Saunders Company; 1948:47.
  39. Kim SW, Paick J, Park DW, et al. Potential predictors of asymptomatic ischemic heart disease in patients with vasculogenic erectile dysfunction. Urology 2001;58(3):441–445. DOI: 10.1016/s0090-4295(01)01210-9.
  40. Kloner RA, Jarow JP. Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol 1999;83(4):576–582. DOI: 10.1016/s0002-9149(98)00916-3.
  41. Kloner RA. Hypertension as a risk for erectile dysfunction: implications for sildenafil use. J Clin Hypertens (Greenwich) 2000;2(1):33–36. PMID: 11416623.
  42. Toblli JE, Stella I, Inserra F, et al. Morphological changes in cavernous tissue in spontaneously hypertensive rats. Am J Hypertens 2000;13(6 Pt 1):686–692. DOI: 10.1016/s0895-7061(99)00268-x.
  43. Prisant LM, Weir MR, Frishman WH, et al. Self reported sexual dysfunction in men and women treated with bisoprolol, hydrochlorothiazide, enalapril, amlodipine, placebo, or bisoprolol/hydrochlorothiazide. J Clin Hypertens (Greenwich) 1999;1(1):22–26. PMID: 11416589.
  44. Party MW. MRC trial of treatment of mild hypertension: principal results. BMJ 1985;291:97–104.
  45. Williams GH. Quality of life and its impact on hypertensive patients. Am J Med 1987;82(1):98–105. DOI: 10.1016/0002-9343(87)90382-2.
  46. Jachuck SJ, Brierley H, Jachuck S, et al. The effect of hypotensive drugs on the quality of life. J R Coll Gen Pract 1982;32(235):103–105. PMID: 7097628.
  47. Wassertheil-Smoller S, Blaufox MD, Oberman A, et al. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med 1991;114(8):613–620. DOI: 10.7326/0003-4819-114-8-613.
  48. Nicolai MPJ, Liem SS, Both S, et al. A review of the positive and negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice. Neth Heart J 2014;22(1):11–19. DOI: 10.1007/s12471-013-0482-z.
  49. Akinyede AA, Nwaiwu O, Fasipe OJ, et al. A prospective study of the effect of antihypertensive medications on the sexual functions of hypertensive adult male patients. Future Sci OA 2020;6(6):FSO479. DOI: 10.2144/fsoa-2020-0030.
  50. Thomas HN, Evans GW, Berlowtiz DR, et al. Antihypertensive medications and sexual function in women: Baseline data from the Systolic Blood Pressure Intervention Trial (SPRINT). J Hypertens 2016;34(6):1224–1231. DOI: 10.1097/HJH.0000000000000911.
  51. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247(12):1707–1714. DOI: 10.1001/jama.1982.03320370021023.
  52. Perez-Stable EJ, Halliday R, Gardiner PS, et al. The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension. Am J Med 2000;108(5):359–365. DOI: 10.1016/s0002-9343(00)00304-1.
  53. Ogihara T, Nakagawa M, Ishikawa H, et al. Effect of manidipine, a novel calcium channel blocker, on quality of life in hypertensive patients. Blood Press Suppl 1992;3:135–139. PMID: 1343283.
  54. Coward RM, Carson CC. Tadalafil in the treatment of erectile dysfunction. Ther Clin Risk Manag 2008;4(6):1315–1330. DOI: 10.2147/tcrm.s3336.
  55. McMahon CG, Lee G, Park JK, et al. Premature ejaculation and erectile dysfunction prevalence and attitudes in the Asia-Pacific region. J Sex Med 2012;9(2):454–465. DOI: 10.1111/j.1743-6109.2011.02507.x.
  56. Montague DK, Jarow J, Broderick GA, et al. AUA guideline on the pharmacologic management of premature ejaculation. J Urol 2004;172(1):290–294. DOI: 10.1097/01.ju.0000132159.61156.ea.
  57. Hatzimouratidis K, Giuliano F, Moncada I, et al. EAU guidelines on erectile dysfunction, premature ejaculation, penile curvature and priapism. Arnhem, the Netherlands: EAU Guidelines Office; 2018.
  58. Bai Y, Pu C, Han P, et al. Selective serotonin reuptake inhibitors plus phosphodiesterase-5 inhibitors for premature ejaculation: a systematic review and meta-analysis. Urology 2015;86(4):758–764. DOI: 10.1016/j.urology.2015.06.045.
  59. Sun Y, Luo D, Yang L, et al. Efficacy of phosphodiesterase-5 inhibitor in men with premature ejaculation: a new systematic review and meta-analysis. Urology 2015;86(5):947–954. DOI: 10.1016/j.urology.2015.06.051.
  60. Men C, Yu L, Yuan H, et al. Efficacy and safety of phosphodiesterase type 5 inhibitors on primary premature ejaculation in men receiving selective serotonin reuptake inhibitors therapy: a systematic review and meta-analysis. Andrologia 2016;48(9):978–985. DOI: 10.1111/and.12540.
  61. Asimakopoulos AD, Miano R, Finazzi Agro E, et al. Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? A systematic review and meta-analysis. J Sex Med 2012;9(9):2404–2416. DOI: 10.1111/j.1743-6109.2011.02628.x.
  62. McMahon CG, McMahon CN, Leow LJ, et al. Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review. BJU Int 2006;98(2):259–272. DOI: 10.1111/j.1464-410X.2006.06290.x.
  63. Dresser MJ, Desai D, Gidwani S, et al. Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors. Int J Impot Res 2006;18(1):104–110. DOI: 10.1038/sj.ijir.3901420.
  64. Modell JG, May RS, Katholi CR. Effect of bupropion-SR on orgasmic dysfunction in nondepressed subjects: a pilot study. J Sex Marital Ther 2000;26(3):231–240. DOI: 10.1080/00926230050084623.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.